Literature DB >> 22240085

Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA).

Mieke Klein Hofmeijer-Sevink1, Neeltje M Batelaan, Harold J G M van Megen, Brenda W Penninx, Danielle C Cath, Marcel A van den Hout, Anton J L M van Balkom.   

Abstract

BACKGROUND: To study the clinical relevance of type of comorbidity and number of comorbid disorders in anxiety disorders. Four groups were compared according to sociodemographic-, vulnerability- and clinical factors: single anxiety disorder, anxiety-anxiety comorbidity, anxiety-depressive comorbidity and "double" comorbidity (i.e. anxiety and depressive comorbidity).
METHODS: Data were obtained from the Netherlands Study of Anxiety and Depression (NESDA). A sample of 1004 participants with a current anxiety disorder was evaluated.
RESULTS: As compared with single anxiety, anxiety-anxiety comorbidity was associated with higher severity, greater chronicity and more treatment. Anxiety-anxiety comorbidity was associated with an earlier age of onset and a more chronic course compared with anxiety-depressive comorbidity, while anxiety-depressive comorbidity was associated with more severe symptoms and more impaired functioning than anxiety-anxiety comorbidity. "Double" comorbidity was associated with higher severity, greater chronicity, more treatment and increased disability. Sociodemographic and vulnerability factors were comparable among the four groups. Limitations A prospective design would be more appropriate to study the outcome. In this study no distinction was made between whether depression or anxiety disorder preceded the current anxiety disorder.
CONCLUSIONS: It is clinical relevant to diagnose and treat comorbidity among anxiety disorders as it is associated with higher severity and more chronicity. Whereas anxiety-anxiety comorbidity has an earlier age of onset and a more chronic course, anxiety-depressive comorbidity leads to more treatment and impaired functioning. "Double" comorbidity leads to even more severity, chronicity and impairment functioning compared with both anxiety-anxiety and anxiety-depressive comorbidity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22240085     DOI: 10.1016/j.jad.2011.12.008

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  31 in total

1.  Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013.

Authors:  Henry C Ndukwe; June M Tordoff; Ting Wang; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2014-10       Impact factor: 3.923

2.  Perinatal Generalized Anxiety Disorder: Assessment and Treatment.

Authors:  Shaila Misri; Jasmin Abizadeh; Shawn Sanders; Elena Swift
Journal:  J Womens Health (Larchmt)       Date:  2015-06-30       Impact factor: 2.681

3.  Neurocognitive Endophenotypes of OCD.

Authors:  Matilde M Vaghi
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Presence and Predictive Value of Obsessive-Compulsive Symptoms in Anxiety and Depressive Disorders.

Authors:  Mieke Klein Hofmeijer-Sevink; Neeltje M Batelaan; Harold J G M van Megen; Marcel A van den Hout; Brenda W Penninx; Anton J L M van Balkom; Danielle C Cath
Journal:  Can J Psychiatry       Date:  2017-05-16       Impact factor: 4.356

5.  Age and remission of personality pathology in the psychotic disorders compared to mood and/or anxiety disorders.

Authors:  Tianhong Zhang; Mary-Jo D Good; Byron J Good; Annabelle Chow; Lanlan Wang; Yunfei Dai; Zeping Xiao
Journal:  Int J Psychiatry Med       Date:  2012       Impact factor: 1.210

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  Discriminant validity, diagnostic utility, and parent-child agreement on the Screen for Child Anxiety Related Emotional Disorders (SCARED) in treatment- and non-treatment-seeking youth.

Authors:  B I Rappaport; D Pagliaccio; D S Pine; D N Klein; J M Jarcho
Journal:  J Anxiety Disord       Date:  2017-08-30

8.  Positive and Negative Affect as Links Between Social Anxiety and Depression: Predicting Concurrent and Prospective Mood Symptoms in Unipolar and Bipolar Mood Disorders.

Authors:  Jonah N Cohen; M Taylor Dryman; Amanda S Morrison; Kirsten E Gilbert; Richard G Heimberg; June Gruber
Journal:  Behav Ther       Date:  2017-07-16

9.  Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type.

Authors:  A M Perkins; U Ettinger; K Weaver; A Schmechtig; A Schrantee; P D Morrison; A Sapara; V Kumari; S C R Williams; P J Corr
Journal:  Transl Psychiatry       Date:  2013-04-16       Impact factor: 6.222

10.  Prevalence, associated factors and predictors of anxiety: a community survey in Selangor, Malaysia.

Authors:  Siti Fatimah Kader Maideen; Sherina Mohd Sidik; Lekhraj Rampal; Firdaus Mukhtar
Journal:  BMC Psychiatry       Date:  2015-10-24       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.